A Phase 2 Study to Evaluate the Anti-Tumor Activity of Single Agent Flotetuzumab in Advanced CD123-Positive Hematological Malignancies
Status: Not yet recruiting
Phase of Trial: Phase II
Latest Information Update: 03 Dec 2019
Price : $35 *
At a glance
- Drugs Flotetuzumab (Primary)
- Indications Acute biphenotypic leukaemia; Blastic plasmacytoid dendritic cell neoplasm; Chronic myeloid leukaemia; Haematological malignancies; Hairy cell leukaemia; Hodgkin's disease; Precursor B-cell lymphoblastic leukaemia-lymphoma; Precursor T-cell lymphoblastic leukaemia-lymphoma; Systemic mastocytosis
- Focus Therapeutic Use
- 29 Nov 2019 Planned initiation date changed from 10 Nov 2019 to 10 Jan 2020.
- 03 Oct 2019 Planned initiation date changed from 10 Sep 2019 to 10 Nov 2019.
- 11 Jul 2019 Planned initiation date changed from 10 Jun 2019 to 10 Sep 2019.